LC
NVCR icon

Lindbrook Capital’s NovoCure NVCR Stock Holding History

Lindbrook Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$26.8K Sell
1,504
-350
-19% -$7.95K ﹤0.01% 1231
2024
Q4 		$55.2K Buy
1,854
+1,213
+189% +$25.7K 0.01% 776
2024
Q3 		$10K Sell
641
-96
-13% -$1.74K ﹤0.01% 1678
2024
Q2 		$12.6K Sell
737
-58
-7% -$1.02K ﹤0.01% 1500
2024
Q1 		$12.4K Buy
795
+446
+128% +$6.56K ﹤0.01% 1454
2023
Q4 		$5.21K Sell
349
-113
-24% -$1.51K ﹤0.01% 1861
2023
Q3 		$7.46K Sell
462
-76,506
-99% -$2.21M ﹤0.01% 1560
2023
Q2 		$3.19M Buy
76,968
+24,299
+46% +$1.51M 0.34% 51
2023
Q1 		$3.17M Buy
52,669
+2,315
+5% +$185K 0.37% 49
2022
Q4 		$3.69M Buy
50,354
+50,183
+29,347% +$3.78M 0.45% 49
2022
Q3 		$13K Buy
171
+125
+272% +$9.75K ﹤0.01% 1206
2022
Q2 		$3K Sell
46
-5
-10% -$377 ﹤0.01% 1813
2022
Q1 		$4K Buy
51
+41
+410% +$3.02K ﹤0.01% 1723
2021
Q4 		$1K Sell
10
-80
-89% -$8.03K ﹤0.01% 1959
2021
Q3 		$10K Sell
90
-53
-37% -$8.01K ﹤0.01% 997
2021
Q2 		$32K Buy
143
+13
+10% +$2.53K 0.01% 620
2021
Q1 		$17K Buy
130
+25
+24% +$3.96K ﹤0.01% 817
2020
Q4 		$18K Buy
105
+5
+5% +$684 ﹤0.01% 723
2020
Q3 		$11K Buy
100
+25
+33% +$2K ﹤0.01% 805
2020
Q2 		$4K Buy
+75
New +$4.93K ﹤0.01% 1188

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Lindbrook Capital's NVCR Position: Q1 2025 in Review

Lindbrook Capital reduced its NovoCure (NVCR) stake by 19% in Q1 2025, selling an estimated $7.95K and leaving 1,504 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1231.

Lindbrook Capital first reported a position in NVCR in Q2 2020 and has held it in 20 quarters since. The position peaked at $3.69M in Q4 2022. 228 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Lindbrook Capital held 1,504 shares of NovoCure worth $26.8K as of Q1 2025.
  • Lindbrook Capital sold 350 NovoCure shares in Q1 2025, an estimated $7.95K.
  • NovoCure made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1231 holding.
  • Lindbrook Capital first reported a position in NovoCure in Q2 2020 and has held it in 20 quarters since.
  • Lindbrook Capital's NovoCure position peaked at $3.69M in Q4 2022.
  • 228 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.